Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (AMRN) delivers innovative cardiovascular therapeutics through advanced lipid science, anchored by its FDA-approved therapy VASCEPA®. This page provides direct access to official company announcements, clinical research updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases covering drug approvals, global expansion efforts, and peer-reviewed study results. Key updates include milestones from the landmark REDUCE-IT trial, intellectual property developments, and strategic partnerships enhancing patient access to cardiovascular care solutions.
All content is sourced from Amarin's corporate communications, ensuring accuracy and timeliness. Bookmark this page for streamlined tracking of AMRN's progress in addressing persistent cardiovascular risk through scientifically validated therapies.
Sarissa Capital Management has expressed deep concern over Amarin's board governance, highlighting the absence of shareholder representation. In 2022, Amarin's stock plummeted by over two-thirds, translating to a loss of more than $840 million in equity for its shareholders. Key issues include delays in the European launch, challenges in securing reimbursement in Germany, and ineffective management responses that led to significant capital destruction. Sarissa, as Amarin's largest shareholder, is pushing for a special meeting to remove Chairman Per Wold-Olsen and appoint new directors to enhance shareholder interests.
Amarin Corporation (NASDAQ:AMRN) announced a requisition by Sarissa Capital Management to convene a Special Meeting of Shareholders. The Company reported significant operational progress and a 70% refreshment of its Board of Directors, enhancing expertise in finance and global commercialization. Positive developments include successful pricing and reimbursement strategies in Europe, stabilization in the U.S. market, and improved cash flow of $4 million in Q4 2022. Amarin is focused on achieving $100 million in cost reductions by mid-2023. A proxy contest with Sarissa may disrupt ongoing strategic efforts.
Sarissa Capital Management is calling for drastic changes to the Amarin Corporation board, citing a lack of credibility and responsiveness to shareholder concerns. Following a shareholder meeting where mistrust towards the board was evident, Sarissa expressed disappointment that their nominee suggestions were ignored. The board's recent acknowledgment of the need for refreshment is seen as insufficient. Sarissa is pursuing a special meeting to add seven directors and remove Chairman Per Wold-Olsen. They warn of legal action if their shareholder rights are obstructed.
Amarin Corporation plc (NASDAQ:AMRN) reported a preliminary revenue of $88-$90 million for Q4 2022, totaling $367-$369 million for the full year, marking the fourth consecutive quarter of revenue stabilization in the U.S. Cash reserves stand at approximately $310 million, with a positive cash flow of $4 million in Q4. The company continues to make progress in European markets, securing positive reimbursement decisions in five countries and pursuing negotiations in others. The CEO emphasized a focus on growth and adaptation to market conditions.
Amarin Corporation plc (NASDAQ:AMRN) has appointed Dr. Murray W. Stewart to its Board of Directors, following a significant board refreshment initiative that has resulted in around 70% new independent directors within the past year. Dr. Stewart brings over 30 years of cardiometabolic academic and industry experience, including roles at GlaxoSmithKline and Rhythm Pharmaceuticals. His appointment aligns with Amarin's strategy to expand into Europe and diversify its product portfolio, enhancing its focus on global, cardiometabolic health.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will speak at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 p.m. ET. This event occurs from January 9-12, 2023, in San Francisco, California. The presentation will be webcast live and available for later viewing on Amarin's Investor Relations webpage.
Amarin focuses on cardiovascular disease management, emphasizing scientific research and clinical trials as it expands its commercial presence.
Amarin Corporation plc (NASDAQ:AMRN) announced the approval of its drug VAZKEPA (icosapent ethyl) by Switzerland's Swissmedic. The drug is indicated for reducing cardiovascular risks in high-risk adults. This marks the sixth approval of the VAZKEPA franchise in 2022. Amarin is concurrently pursuing national pricing and reimbursement, expected to complete in 2023. The approval supports Amarin's strategy to strengthen its European operations, having established a regional hub in Zug, Switzerland, in 2021, which hosts over 30 employees dedicated to commercial and medical roles.
Amarin Corporation announced that Australia's Therapeutic Goods Administration (TGA) has approved VAZKEPA (icosapent ethyl) for reducing the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk and elevated triglycerides. This marks the fifth regulatory approval for the VAZKEPA franchise in key international markets in 2022. The company will initiate the reimbursement process to support commercialization in Australia, backed by patents providing market exclusivity into the early 2030s.
Amarin Corporation (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. Mikhail's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).
This event will be webcast live, with an archived version available on Amarin's Investor Relations website. The company focuses on advancing cardiovascular disease management through scientific research and clinical trials.
Amarin Corporation presents key findings from the RESPECT-EPA study at the AHA 2022 Scientific Sessions, highlighting the cardiovascular risk reduction benefits of eicosapentaenoic acid (EPA) for patients with coronary artery disease (CAD). The study demonstrated a 21.5% reduction in cardiovascular risk (p=0.054) and a 26.6% reduction in a secondary endpoint (p=0.03). In contrast, the PROMINENT study reported no cardiovascular benefits from the fibrate class for high-risk patients. The results reinforce the therapeutic value of VASCEPA/VAZKEPA in managing cardiovascular risk alongside statin therapy.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
